Category: BCMA

  • ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

    Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a future rivalry if they get regulatory approval. J&J’s Janssen pharma division gave an update on its MajesTEC-1 study of teclistamab, its already-filed BCMAxCD3 bispecific, in RRMM patients who had […]

  • BCMA Targeted Therapies Summit

    With the undeniable excitement in the BCMA field over the past few months, the BCMA Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline. Pick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to […]

  • GSK nabs FDA approval for first-in-class multiple myeloma drug

    Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.